Cui Jing, Liu Yanfei, Li Yiwen, Xu Fengqin, Liu Yue
Cardiovascular Centre of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
National Clinical Research Centre for Chinese Medicine Cardiology, Beijing, China.
Front Cardiovasc Med. 2021 Feb 24;8:644189. doi: 10.3389/fcvm.2021.644189. eCollection 2021.
Type 2 diabetes mellitus (T2DM) and its complications are seriously affecting public health worldwide. Myocardial infarction (MI) is the primary cause of death in patients with T2DM. T2DM patients without a history of coronary artery disease (CAD) have the same risk of major coronary events as those with CAD; T2DM patients with a history of MI have >40% risk of recurrence of MI. Thus, CAD in patients with T2DM needs to be treated actively to reduce the risk of MI. The cardiology community focused on the role of T2DM in the development of CAD and on the related issues of T2DM and MI with respect to comorbidities, prognosis, drug therapy, and heredity. In this mini review, the latest progress of clinical evidence-based research between T2DM and MI in recent years was reviewed, and the possible research directions in this field were considered and prospected.
2型糖尿病(T2DM)及其并发症严重影响着全球公众健康。心肌梗死(MI)是T2DM患者的主要死因。无冠状动脉疾病(CAD)病史的T2DM患者发生主要冠状动脉事件的风险与有CAD病史的患者相同;有MI病史的T2DM患者复发MI的风险超过40%。因此,需要积极治疗T2DM患者的CAD以降低MI风险。心脏病学界关注T2DM在CAD发生发展中的作用以及T2DM与MI在合并症、预后、药物治疗和遗传方面的相关问题。在本综述中,回顾了近年来T2DM与MI之间临床循证研究的最新进展,并对该领域可能的研究方向进行了思考和展望。